IBD SPOTLIGHT




FERRING

PHARMACEUTICALS

... initial clinical activity and treatment response by 4 weeks may predict long-term remission in children newly diagnosed with UC?

Predictors of responses to 5-ASA with or without corticosteroid induction therapy were studied prospectively in the PROTECT study¹⁻³ at 4 weeks, 12 weeks and 52 weeks



These findings could have an immediate impact on clinical practice by providing specific parameters for initial disease activity, laboratory test results, and histologic features, as well as early response to standardised therapy, to guide therapeutic decisions in pediatric UC^{1,2}

5-ASA: 5-aminosalicylic acid; CS: corticosteroids; HPF: high-powered field; PUCAI: Pediatric Ulcerative Colitis Activity Index; UC: Ulcerative colitis

- 1. Hyams JS et al. Lancet 2019; 393: 1708- 3. Colman RJ et al. Frontiers in pediatrics 20
 - 2021; 9: 634739.
- 2. Hyams JS et al. Lancet Gastroenterol Hepatol 2017; 2: 855-68.
- 4. Turner D et al. J Pediatr Gastroenterol Nutr 2018; 67(2): 257-291.

CA-COR-2200002 | V1.0 | February 2022

FERRING and the FERRING PHARMACEUTICALS logo are trademarks of Ferring B.V. ©2022 Ferring B.V.